Novo Nordisk‘s NVO CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medicine and infrequently hailed as a “miracle” weight reduction drug, Ozempic will quickly be eligible for U.S. authorities worth negotiations, doubtlessly inside the subsequent yr.
What Occurred: Jorgensen is scheduled to testify earlier than a Senate committee on Tuesday to debate U.S. pricing for Ozempic and the load loss drug Wegovy. The feedback align with Wall Avenue analysts’ expectations that Ozempic can be on the 2027 worth negotiation listing, which can be introduced in February 2025, Reuters reported.
Final week, one other Novo government indicated that Ozempic would “very seemingly” be included within the 2027 listing. A month’s provide of Ozempic at the moment lists at $935.77 within the U.S., whereas Wegovy lists for $1,349.02 per 30 days, though insurance coverage usually reduces these prices.
The Inflation Discount Act of 2022 permits Medicare to barter costs for pricey prescribed drugs, impacting thousands and thousands of People. Each Ozempic and Wegovy have confronted scrutiny from lawmakers over their excessive costs within the U.S.
Jorgensen famous that the web worth of Ozempic has decreased by about 40% since its U.S. introduction, and Wegovy’s internet worth has equally declined since its launch. He expects internet costs for each medicine to proceed to fall beneath present market circumstances.
See Additionally: Lengthy-Time period Medical Hashish Use Has No Important Dangerous Results On Reminiscence Or Impulse Management, New Research
Why It Issues: The upcoming Senate listening to, scheduled for Tuesday, will see Lars Fruergaard Jorgensen face rigorous questioning from U.S. lawmakers concerning the excessive costs of Ozempic and Wegovy. Senator Bernie Sanders, chair of the Senate Committee on Well being, Training, Labor, and Pensions, has been vocal in regards to the exorbitant prices of those drugs.
In a earlier interview, Jorgensen defended the excessive U.S. costs, arguing that these medicine assist scale back the financial burden of obesity-related well being points, which prices the U.S. over $400 billion yearly. He dismissed accusations that Novo Nordisk operates as a drug cartel as “unfounded.”
Moreover, the problem of counterfeit Ozempic has emerged as a big concern. Criminals have been distributing faux variations of the drug by forging batch numbers, which has grow to be a world subject. The World Well being Group and Interpol have each issued warnings about these counterfeit merchandise.
Learn Subsequent:
Photograph by way of Shutterstock
This story was generated utilizing Benzinga Neuro and edited by Pooja Rajkumari
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
